Japan
· Delayed Price · Currency is JPY | Market Cap | 12.51T |
| Revenue (ttm) | 1.22T |
| Net Income (ttm) | 410.15B |
| Shares Out | 1.65B |
| EPS (ttm) | 249.23 |
| PE Ratio | 30.50 |
| Forward PE | 28.64 |
| Dividend | 100.00 (1.32%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 1,153,300 |
| Average Volume | 2,613,895 |
| Open | 7,520.00 |
| Previous Close | 7,562.00 |
| Day's Range | 7,520.00 - 7,644.00 |
| 52-Week Range | 4,572.00 - 8,655.00 |
| Beta | 0.76 |
| RSI | 49.69 |
| Earnings Date | Jul 24, 2025 |
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys... [Read more]
Financial Performance
In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.
Financial StatementsNews
Japanese Stocks Close Lower Amid Global Trade Tensions
Japanese stocks ended lower as growing U.S.-China trade tensions weighed on the global economic outlook. Electronics, pharmaceutical and auto shares led the losses. Sony Group dropped 7.4%, Chugai Pha...
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q4 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q4 2024 Earnings Conference Call January 30, 2025 3:30 AM ETCompany ParticipantsKae Miyata - Head of Corporate...
Chugai Pharmaceutical Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation
Full Year 2024 Chugai Pharmaceutical Co Ltd Earnings Presentation Transcript
Full Year 2024 Chugai Pharmaceutical Co Ltd Earnings Presentation Transcript
Chugai Pharmaceutical GAAP EPS of $253.36, revenue of $1.17B
Chugai Pharmaceutical Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Roche Holding AG (OTC: RHHBY) reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co (NYSE: LLY) to acquire the drug, now known as orforglipron, for just ...
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q2 2024 Earnings Conference Call July 24, 2024 4:00 AM ET Company Participants Kae Miyata - Head of Corporate Communications Osamu Okuda - President and C...
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q1 2024 Earnings Conference Call April 24, 2024 5:00 AM ET